Loading
Adding the proteasome inhibitor bortezomib to standard chemotherapy for children with newly diagnosed acute myeloid leukaemia did not help them live longer or relapse less, and it caused more nerve damage and intensive care admissions.
Report of the randomised bortezomib question in the Children's Oncology Group phase 3 AAML1031 trial: 1,097 patients under 30 with de novo acute myeloid leukaemia were randomised to standard chemotherapy with (n 555) or without (n 542) bortezomib 1.3 mg/m2 on days 1, 4 and 8 of each course.
Remission induction rates were the same (89 against 91 percent), three-year event-free survival was 44.8 against 47.0 percent and overall survival 63.6 against 67.2 percent. Bortezomib was associated with more peripheral neuropathy and intensive care unit admissions during the first course.
Bortezomib should not be added to standard chemotherapy for childhood acute myeloid leukaemia; the trial's FLT3-ITD sorafenib cohorts were reported separately.
Shares Haematologica, Acute myeloid leukaemia.
Shares Haematologica, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia.